VSIG4 and metabolic dysfunction-associated steatotic liver disease: Moreover, VSIG4 has been reported to be markedly down-regulated in fatty livers in patients with nonalcoholic fatty liver disease and in obese mice, whereas the loss of VSIG4 has been shown to accelerate lipid deposition, fibrosis and the severity of inflammatory responses (Li et al., 2019).